-
公开(公告)号：US09802880B2
公开(公告)日：2017-10-31
申请号：US15122160
申请日：2015-02-12
IPC分类号： C07C50/28 , A61K31/122 , A61K31/13 , A61K31/215 , C07C69/757 , C07C225/28
CPC分类号： C07C50/28 , A61K31/122 , A61K31/13 , A61K31/215 , C07C69/757 , C07C69/95 , C07C225/28 , C07C2601/14 , C07C2601/16
摘要： The present invention relates to novel cannabigerol quinone derivatives of formula (I) wherein R is the carbon atom of a linear or branched group, represented by: aryl, alkenyl, alkynyl or alcoxycarbonil groups; or wherein R is the nitrogen atom of a linear or branched group, represented by: alkylamino, arylamino, alkenylamino or alkynylamino groups; or, alternatively, R represents a bond between 2 molecules of formula (I) forming a dimer. The invention also relates to the use of any of the compounds of formula (I) as medicaments in therapy, particularly for treating PPARg-related diseases due to their high PPARg agonistic effect lacking electrophilic (Nrf2 activation) and cytotoxic activities. This invention also provides pharmaceutical compositions comprising said compounds and method of treating diseases with said compounds.
-
公开(公告)号：US20220226259A1
公开(公告)日：2022-07-21
申请号：US17628415
申请日：2020-04-29
摘要： It is disclosed a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof: wherein R1 is a linear alkyl group of 3 or 5 carbon atoms, and R2 is: and a pharmaceutical composition comprising the same, for use in the treatment of a disease whose treatment benefits from inhibiting or reducing Notch1 expression levels in cells, and/or benefits from inhibiting or reducing Notch1 levels in cells, and/or benefits from inhibiting or reducing Notch1 signaling dependent proteins levels in cells.
As a consequence, present invention also relates to said compound of formula (I), and to the pharmaceutical composition comprising the same, for use in suppressing cancer stem cells, as well as, for use in reducing solid tumor development, metastasis or chemo/radio-resistance, promoted by cancer stem cells.-
公开(公告)号：US20170247308A1
公开(公告)日：2017-08-31
申请号：US15122160
申请日：2015-02-12
IPC分类号： C07C50/28 , A61K31/122 , C07C225/28 , A61K31/13 , C07C69/757 , A61K31/215
CPC分类号： C07C50/28 , A61K31/122 , A61K31/13 , A61K31/215 , C07C69/757 , C07C69/95 , C07C225/28 , C07C2601/14 , C07C2601/16
摘要： The present invention relates to novel cannabigerol quinone derivatives of formula (I) wherein R is the carbon atom of a linear or branched group, represented by: aryl, alkenyl, alkynyl or alcoxycarbonil groups; or wherein R is the nitrogen atom of a linear or branched group, represented by: alkylamino, arylamino, alkenylamino or alkynylamino groups; or, alternatively, R represents a bond between 2 molecules of formula (I) forming a dimer. The invention also relates to the use of any of the compounds of formula (I) as medicaments in therapy, particularly for treating PPARg-related diseases due to their high PPARg agonistic effect lacking electrophilic (Nrf2 activation) and cytotoxic activities. This invention also provides pharmaceutical compositions comprising said compounds and method of treating diseases with said compounds.
-
公开(公告)号：US09701618B2
公开(公告)日：2017-07-11
申请号：US15304810
申请日：2014-04-16
IPC分类号： C07C225/28 , C07C69/95
CPC分类号： C07C225/28 , C07B2200/07 , C07C69/95 , C07C2601/16 , C07C2602/42
摘要： The present invention relates to novel cannabidiol quinone derivatives of formula (I) (I) wherein R is the carbon atom of a, linear or branched group, represented by: alkyl, aryl, alkenyl, alkynyl, acyl or alkoxycarbonyl groups; or wherein R is the nitrogen atom of a, linear or branched group represented by: alkylamine, arylamine, alkenylamine or alkynylamine groups. The invention also relates to the use of any of the compounds of formula (I) as medicaments in therapy, particularly for treating diseases and conditions responsive to PPARg modulation due to their high PPARg agonistic effect lacking electrophilic (Nrf2 activation) and cytotoxic activities. This invention also provides pharmaceutical compositions comprising said compounds and method of treating diseases with said compounds.
-
公开(公告)号：US20170044092A1
公开(公告)日：2017-02-16
申请号：US15304810
申请日：2014-04-16
IPC分类号： C07C225/28 , C07C69/95
CPC分类号： C07C225/28 , C07B2200/07 , C07C69/95 , C07C2601/16 , C07C2602/42
摘要： The present invention relates to novel cannabidiol quinone derivatives of formula (I) (I) wherein R is the carbon atom of a, linear or branched group, represented by: alkyl, aryl, alkenyl, alkynyl, acyl or alkoxycarbonyl groups; or wherein R is the nitrogen atom of a, linear or branched group represented by: alkylamine, arylamine, alkenylamine or alkynylamine groups. The invention also relates to the use of any of the compounds of formula (I) as medicamentsin therapy, particularly for treating diseases and conditions responsive to PPARg modulation due to their high PPARg agonistic effect lacking electrophilic (Nrf2 activation) and cytotoxic activities. This invention also provides pharmaceutical compositions comprising said compounds and method of treating diseases with said compounds.
摘要翻译： 本发明涉及式（I）（I）的新型大二酚醌衍生物，其中R是直链或支链基团的碳原子，由烷基，芳基，烯基，炔基，酰基或烷氧基羰基表示; 或其中R为由烷基胺，芳基胺，链烯基胺或炔基胺基团表示的直链或支链基团的氮原子。 本发明还涉及任何式（I）化合物作为治疗药物的用途，特别是用于治疗由于其不具有亲电子（Nrf2活化）和细胞毒活性的高PPARg激动作用而对PPARg调节有反应的疾病和病症。 本发明还提供包含所述化合物的药物组合物和用所述化合物治疗疾病的方法。
-
-
-
-
搜索结果
5 条记录 (耗时 0.014 秒)
